VISEN Pharmaceuticals (Taiwan) Ltd.

News

All News Partner News

                                            
                                17

                                Nov
2022

Partner News
VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin Currently

                                07

                                Nov
2022

Partner News
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

                                26

                                Aug
2021

Partner News
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

                                13

                                Jan
2022

Partner News
Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

                                13

                                Mar
2022

Partner News
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

About Us

Technology

Disease Area

Health Education

News

Career

News

VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin Currently

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

News

VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin Currently

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

This website may be linked to websites provided by other organizations, but these websites are not controlled by our company. Our company will not make any guarantee or be liable for any responsibility for the content displayed by these websites.

This website may be linked to websites provided by other organizations, but these websites are not controlled by our company. Our company will not make any guarantee or be liable for any responsibility for the content displayed by these websites.

This website may be linked to websites provided by other organizations, but these websites are not controlled by our company. Our company will not make any guarantee or be liable for any responsibility for the content displayed by these websites.

This website may be linked to websites provided by other organizations, but these websites are not controlled by our company. Our company will not make any guarantee or be liable for any responsibility for the content displayed by these websites.

This website may be linked to websites provided by other organizations, but these websites are not controlled by our company. Our company will not make any guarantee or be liable for any responsibility for the content displayed by these websites.

Disclaimer

想多了解更多的疾病知識!! Join Us